NASDAQ:NITENightstar Therapeutics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nightstar Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range$25.41MA: $25.41▼$25.4152-Week Range N/AVolume40 shsAverage Volume185,808 shsMarket Capitalization$852.25 millionP/E RatioN/ADividend YieldN/ABeta2.84 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Nightstar Therapeutics. Previous Next 2.7 Community Rank Outperform VotesNightstar Therapeutics has received 225 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNightstar Therapeutics has received 194 “underperform” votes. (Add your “underperform” vote.)Community SentimentNightstar Therapeutics has received 53.70% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Nightstar Therapeutics and other stocks. Vote “Outperform” if you believe NITE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NITE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNightstar Therapeutics does not currently pay a dividend.Dividend GrowthNightstar Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nightstar Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 32.83% of the stock of Nightstar Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nightstar Therapeutics are expected to grow in the coming year, from ($1.56) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nightstar Therapeutics is -20.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nightstar Therapeutics is -20.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.67 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NITE Previous Symbol CUSIPN/A CIK1711675 Webwww.nightstartx.com Phone44-20-7062-2777Debt Debt-to-Equity RatioN/A Current Ratio8.54 Quick Ratio8.54Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.89 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($1.26) Net Income$-36,860,000.00 Net MarginsN/A Return on Equity-30.89% Return on Assets-27.65%Miscellaneous Employees47 Outstanding Shares33,540,000Market Cap$852.25 million Next Earnings DateN/A OptionableNot Optionable Receive NITE News and Ratings via Email Sign-up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter. Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions How were Nightstar Therapeutics' earnings last quarter? Nightstar Therapeutics PLC (NASDAQ:NITE) announced its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.13. View Nightstar Therapeutics' earnings history. Has Nightstar Therapeutics been receiving favorable news coverage? Media coverage about NITE stock has trended very negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nightstar Therapeutics earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutNightstar Therapeutics. Who are some of Nightstar Therapeutics' key competitors? Some companies that are related to Nightstar Therapeutics include bluebird bio (BLUE), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Novavax (NVAX), Fate Therapeutics (FATE), Alector (ALEC), Bill.com (RVMD), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Regenxbio (RGNX), I-Mab (BDTX), Mesoblast (MESO) and Twist Bioscience (TWST). View all competitors. What other stocks do shareholders of Nightstar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nightstar Therapeutics investors own include Canopy Growth (CGC), Cronos Group (CRON), Portola Pharmaceuticals (PTLA), Sorrento Therapeutics (SRNE), Ligand Pharmaceuticals (LGND), NVIDIA (NVDA), Oncomed Pharmaceuticals (OMED), Neurocrine Biosciences (NBIX), Sangamo Therapeutics (SGMO) and Supernus Pharmaceuticals (SUPN). Who are Nightstar Therapeutics' key executives? Nightstar Therapeutics' management team includes the following people: Mr. David Fellows, CEO & Director (Age 62)Mr. Senthil Vel Sundaram, Chief Financial Officer (Age 41)Dr. Gregory Scott Robinson, Chief Scientific Officer (Age 60)Brian Luque, Sr. Mang. of Investor RelationsMr. Seokho Bryan Yoon Esq., Gen. Counsel & Sec. (Age 40) When did Nightstar Therapeutics IPO? (NITE) raised $76 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers. What is Nightstar Therapeutics' stock symbol? Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE." How big of a company is Nightstar Therapeutics? Nightstar Therapeutics has a market capitalization of $0.00. The company earns $-36,860,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Nightstar Therapeutics employs 47 workers across the globe. What is Nightstar Therapeutics' official website? The official website for Nightstar Therapeutics is www.nightstartx.com. How can I contact Nightstar Therapeutics? Nightstar Therapeutics' mailing address is 10 MIDFORD PLACE 2ND FLOOR, LONDON X0, W1T5BJ. The company can be reached via phone at 44-20-7062-2777 or via email at [email protected] This page was last updated on 5/30/2020 by MarketBeat.com Staff
